(Q24241489)

English

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

0 references

1 reference

Europe PubMed Central

title

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease (English)

0 references

0 references

0 references

Anthony K Akobeng

1

0 references

Pieter C Stokkers

series ordinal

2

0 references

publication date

15 April 2009

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Thalidomide as "salvage" therapy for patients with delayed hypersensitivity response to infliximab: a case series

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

THALIDOMIDE AND CONGENITAL ABNORMALITIES

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD007351.PUB2

retrieved

21 January 2018

Protein kinase C-dependent effects on leukocyte migration of thalidomide

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19370685

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New life in a sleeper: thalidomide and Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19370685

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19370685

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New insights into the pharmacological and toxicological effects of thalidomide.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19370685

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/19370685

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/14651858.CD007351.PUB2

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4690195

OpenCitations bibliographic resource ID

4690195

1 reference

stated in

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4690195

PMC publication ID

7207562

0 references

PubMed publication ID

19370685

0 references

(Q24241489)

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)